Chris Pasquale
Stock Analyst at Guggenheim
(n/a)
# 4,754
Out of 4,828 analysts
6
Total ratings
n/a
Success rate
-28.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Pasquale
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZIMV ZimVie | Initiates: Neutral | n/a | $8.76 | - | 1 | Mar 18, 2022 | |
| ICAD iCAD, Inc. | Downgrades: Neutral | n/a | $3.60 | - | 2 | Jan 18, 2022 | |
| DXCM DexCom | Upgrades: Buy | $145 | $84.67 | +71.25% | 1 | Jan 7, 2022 | |
| COO The Cooper Companies | Upgrades: Buy | $124 | $82.26 | +50.44% | 1 | Jan 3, 2022 | |
| PRCT PROCEPT BioRobotics | Initiates: Buy | $45 | $53.11 | -15.27% | 1 | Oct 11, 2021 | |
ZimVie
Mar 18, 2022
Initiates: Neutral
Price Target: n/a
Current: $8.76
Upside: -
iCAD, Inc.
Jan 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.60
Upside: -
DexCom
Jan 7, 2022
Upgrades: Buy
Price Target: $145
Current: $84.67
Upside: +71.25%
The Cooper Companies
Jan 3, 2022
Upgrades: Buy
Price Target: $124
Current: $82.26
Upside: +50.44%
PROCEPT BioRobotics
Oct 11, 2021
Initiates: Buy
Price Target: $45
Current: $53.11
Upside: -15.27%